Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients

Leukemia and Lymphoma

Volumn 42, Issue 3, 2001, Pages 317-327

  Chen, C L ^a   Rawwas, J ^a   Sorrell, A ^a   Eddy, L ^a   Uckun, F M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Bioavailability; Etoposide; Pharmacokinetic

Indexed keywords

ETOPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CANCER RECURRENCE; CELL LINEAGE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TIME;

EID: 0034898603     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109064588     Document Type: Article

References (57)

1. The clinical pharmacology of etoposide and teniposide
2. Etoposide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer
3. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′-demethyl-9-(4,6-O-2-thenylidene-β-D-glucopyranoside) (NSC-122819)
4. The clinical pharmacology of VM26 and VP-16-213: A brief overview
5. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins
6. Podophyllotoxins: Current status and recent development
7. Mechanism of action of antitumor drug etoposide: A review
8. The activity of etoposide (VP16-213) and teniposide (VM-26) against human lung tumor cells in vitro: Cytotoxicity and DNA breakage
9. Inhibition of the DNA catenation activity by VP-16-213 and VM-26
10. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
11. Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide (VM-26)
12. Free radical metabolism of VP- 16 and inhibition of anthracycline-induced lipid peroxidation
13. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4
14. Cytochrome P450-mediated O-demethylation: A route in the metabolic activation of etoposide
15. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
16. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 × 100 mg, 2 × 50 mg, and 4 × 25 mg of oral etoposide daily for 21 days
17. Palliative cytoreduction in refractory acute leukemia: A retrospective study of 57 adult patients
18. Chronic daily administration of oral etoposide - A phase I trial
19. 21-day schedule oral etoposide in children - A feasibility study
20. Ten-day schedule oral etoposide therapy in advanced childhood malignancies
21. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide
22. Phase I study of oral etoposide in children with refractory solid tumors
23. Phase II study of 21 day schedule oral etoposide in children
24. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors
25. Oral chemotherapy agents in the treatment of leukemia
26. Highly sensitive liquid chromatography-electrospray mass spectrometry (LC-MS) method for the determination of etoposide levels in human serum and plasma
27. In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [(4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline]
28. Pharmacokinetics of TXU(Anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus (HIV)-1
29. Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-240) HPLC method
30. Pharmacokinetics and biological activity of the novel mast cell inhibitor, 4-(3′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice
31. Clinical Pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies
32. Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications
33. Pharmacokinetics
34. Ultrafiltration and subsequent high performance liquid chromatography for in vivo determinations of the protein binding of etoposide
35. Chronic oral etoposide
36. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma
37. Variable bioavailability following repeated oral doses of etoposide
38. Inter-and intrapatient variability in etoposide kinetics with oral and intravenous drug administration
39. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: Therapeutic and pharmacoeconomic perspectives
40. Pharmacokinetics of etoposide (VP-16) in children and adolescents with refractory solid tumors
41. Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation
42. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors
43. Pharmacokinetics of teniposide (VM-26) and etoposide (VP-16-213) in children with cancer
44. Bioavailability and pharmacokinetics of etoposide (VP-16)
45. Etoposide pharmacokinetics in patients with normal and abnormal organ functions
46. Pharmacokinetics of anticancer drugs in children
47. Etoposide (VP-16-213). Current status of an active anticancer drug
48. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide
49. The effect of dose on the bioavailability of oral etoposide
50. Pharmacokinetic aspects of oral administration of etoposide
51. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
52. Altered protein binding of etoposide in patients with cancer
53. In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia: Relation to plasma concentrations and protein binding
54. Population pharmacokinetics of total and unbound etoposide
55. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients
56. Human cytochrome P450 metabolism of teniposide and etoposide
57. Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection